drugset / Trial / NCT01798745
A Study to Assess the Pharmacokinetics and Pharmacodynamics of JNJ-54452840 in Participants With Heart Failure and Anti-beta1-adrenergic Receptor Autoantibodies
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to assess the pharmacokinetics (ie, how the body affects the drug) and pharmacodynamics (ie, how the drug affects the body) of JNJ-54452840 in participants with heart failure and anti-beta1-adrenergic receptor autoantibodies. The safety and tolerability of JNJ-54452840 will also be assessed.
Timeline
- Start
- 2014-11
- Primary completion
- 2015-12
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MIBENRATIDE | Protein / enzyme biologic | 20 mg | Intravenous |
| Subject | MIBENRATIDE | Protein / enzyme biologic | 80 mg | Intravenous |
| Subject | MIBENRATIDE | Protein / enzyme biologic | 160 mg | Intravenous |
| Subject | MIBENRATIDE | Protein / enzyme biologic | 240 mg | Intravenous |